Medical Advocates
HIV Infection/Disease
  Non-Hodgkin’s Lymphoma Drugs
   
Antiretrovirals
 Doxorubicin
 Rituximab
Miscellaneous Therapies
     
     






 
Non-Hodgkin’s Lymphoma Main New/Newsworthy Home Page
Last Update:  November 25, 2008
.Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Antiretrovirals
       

     Journal Papers, Abstracts, and Commentaries  

 
Highly Active Antiretroviral Therapy is Associated with Improved Survival among Patients with
AIDS-Related Primary Central Nervous System
Diamond C, Taylor TH, Im T
Curr HIV Res. 2006 Jul;4(3):375-8.
 Abstract
 
The changing face of HIV-associated lymphoma: what can we learn about optimal therapy
in the post highly active antiretroviral therapy era?
Clayton A, Mughal T.
Hematol Oncol. 2005 Jun 30;22(3):111-120
 Abstract
 
Pharmacokinetic interaction between chemotherapy for non-Hodgkin’s lymphoma and
protease inhibitors in HIV-1-infected patients.
Cruciani M, Gatti G, Vaccher E, et al
 J Antimicrob Chemother. 2005 Feb 22;
 Abstract
 
Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and
pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin’s
lymphoma.
Toffoli G, Corona G, Cattarossi G. et al
Ann Oncol. 2004 Dec;15(12):1805-1809.
 Abstract
 
Impact of Concomitant Antiblastic Chemotherapy and Highly Active Antiretroviral Therapy
on Human Immunodeficiency Virus (HIV) Viremia and Genotyping in HIV-Infected Patients
with Non-Hodgkin Lymphoma.
Simonelli C, Zanussi S, Cinelli R, et al  
Clin Infect Dis. 2003 Sep 15;37(6):820-7.
 Abstract
 
Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active
antiretroviral therapy.
Gerard L, Galicier L, Boulanger E, et al. 
AIDS 2003 Jan 3;17(1):81-87
 Abstract
 
Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi
sarcoma  or non-Hodgkin lymphoma.
Tam HK, Zhang ZF, Jacobson LP, et al.
Int J Cancer 2002 Apr 20;98(6):916-22
 Abstract
 
 
       
     Conference Reports, Abstracts, and Posters
 
 
PDF POSTER
 Decreased Cases of and Improved Survival from AIDS-associated Non-Hodgkin’s
Lymphoma in the Era of Highly Active Antiretroviral Therapy
C Diamond, T H Taylor,  H A Culver, et al.
 (11 CROI)
 PDF Poster       Abstract
 
Doxorubicin
       

     Journal Papers, Abstracts, and Commentaries  

 
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active
antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s
lymphoma.
Xicoy B, Ribera JM, Miralles P, et al 
Haematologica. 2007 Feb;92(2):191-198.
 Abstract

Liposome-Encapsulated Doxorubicin in Combination With Standard Agents
(cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed
AIDS-Related Non-Hodgkin’s Lymphoma: Results of Therapy and Correlates of Response.
Levine AM, Tulpule A, Espina B, et al
Clin Oncol. 2004 Jul 1;22(13):2662-70.
 Abstract
Rituximab
       

     Journal Papers, Abstracts, and Commentaries  

 
Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin’s
Lymphoma.
Boue F, Gabarre J, Gisselbrecht C, et al
J Clin Oncol. 2006 Aug 8;
Abstract

Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP
with or without rituximab in patients with HIV-associated non-Hodgkin’s lymphoma:
AIDS-malignancies consortium trial 010.
Kaplan LD, Lee JY, Ambinder RF, et al 
Blood. 2005 May 24;
 Abstract

Rituximab plus infusional cyclophosphamide, doxorubicin and etoposide (R-CDE) in HIV-
associated non-Hodgkin’s lymphoma: pooled results from three phase II trials.
Spina M, Jaeger U, Sparano JA.et al 
Blood. 2004 Nov 18;
Abstract
 
Infusional CDE with rituximab for the treatment of human immunodeficiency virus-
associated non-Hodgkin’s lymphoma: preliminary results of a phase I/II study.
Tirelli U, Spina M, Jaeger U, et al.
Recent Results Cancer Res 2002;159:149-53
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  CONFERENCE PDF POSTER
 Treatment of AIDS-related Lymphoma: Rituximab May Be Beneficial Even in Severely
Immunosuppressed Patients
C Wyen, G Faetkenheuer, M Oette, et al
 (15th CROI)
 PDF Poster     Abstract
Miscellaneous Therapies
       

     Journal Papers, Abstracts, and Commentaries  

 
Human immunodeficiency virus-associated diffuse non-Hodgkin’s lymphoma in Venezuelan
patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone
without routine use of granulocyte-colony stimulating factor.
Hernandez DE, Hernandez AE 
Eur J Cancer Care (Engl). 2006 Dec;15(5):493-6.
 Abstract.

Treatment of AIDS Related Non-Hodgkin’s Lymphoma with Combination Mitoguazone
Dihydrochloride and Low Dose Chop Chemotherapy: Results of a Phase II study.
Tulpule A, Espina BM, Pedro Santabarbara AB, et al
Invest New Drugs. 2004 Jan;22(1):63-8
 Abstract.
 

High-Dose Cytosine-Arabinoside and Cisplatin Regimens as Salvage Therapy for
Refractory or Relapsed AIDS-Related Non-Hodgkin’s Lymphoma.
Bi J, Espina BM, Tulpule A et al.
 J Acquir Immune Defic Syndr 2001 Dec  15;28(5):416-421
 Abstract
 
Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional
cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40
patients.
Spina M, Vaccher E, Juzbasic S, Milan I, et al.
 Cancer 2001 Jul 1;92(1):200-6
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  The impact of concomitant antiblastic chemotherapy and HAART on HIV-viraemia and
resistance profile in HIV-infected patients with non-Hodgkin’s lymphoma 
C Simonelli, S Zanussi, R.Cinelli, et al.
(1st European HIV Drug Resistance Workshop)
Abstract

Non-Hodgkin’s Lymphoma Main New/Newsworthy Home Page

HIV-Related  Non-Hodgkin’s Lymphoma Drugs